

# **Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines**

## **CHINA NEW ENERGY GROUP CO. (Renamed THRIVE GLOBAL BIOSAFETY INC.)**

8514 South Sagewood Road  
Spokane, WA 99223

---

1 5092301177  
<https://thrivebiosafety.com/>  
[guy@thrivebiosafety.com](mailto:guy@thrivebiosafety.com)  
8748

## **Quarterly Report**

**For the period ending September 30, 2023 (the “Reporting Period”)**

### **Outstanding Shares**

The number of shares outstanding of our Common Stock was:

7,266,940,246 as of September 30, 2023

107,070,281 as of December 31, 2022

### **Shell Status**

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

### **Change in Control**

Indicate by check mark whether a Change in Control<sup>1</sup> of the company has occurred over this reporting period:

Yes: ☐ No: ☒

---

<sup>1</sup> “Change in Control” shall mean any events resulting in:

- (i) Any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

**1) Name and address(es) of the issuer and its predecessors (if any)**

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

China New Energy Group, Company.

10/04/2023 Thrive Precision Health Inc. changed its name from Thrive Global Biosafety Inc.

04/03/2023 Thrive Global Biosafety Inc. changed its name from China New Energy Group Company

05/29/2008 CNER Symbol change from TVHT to CNER

Travel Hunt Holdings, Inc. until 5-2008

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

10-11-07 State of Incorporation Florida changed to Delaware.

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

None

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None

The address(es) of the issuer's principal executive office:

8514 South Sagewood Road  
Spokane, WA 99223

The address(es) of the issuer's principal place of business:

☒ *Check if principal executive office and principal place of business are the same address:*

\_\_\_\_\_

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: ☒ Yes: ☐ If Yes, provide additional details below:

\_\_\_\_\_

**2) Security Information**

**Transfer Agent**

Name: Equiniti Trust Company

Phone: 651-306-4341

Email: [Valeen.Nowicki@equiniti.com](mailto:Valeen.Nowicki@equiniti.com)

Address: 1110 Centre Pointe Curve Suit 101, Mendota Heights, MN 55120

**Publicly Quoted or Traded Securities:**

*The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.*

Trading symbol:	CNER
Exact title and class of securities outstanding:	Common
CUSIP:	16944P109
Par or stated value:	.001
Total shares authorized:	10,000,000,000 as of date: September 30, 2023
Total shares outstanding:	<u>7,266,940,246</u> as of date: September 30, 2023
Total number of shareholders of record:	195 as of date: September, 2023

*All additional class(es) of publicly quoted or traded securities (if any):*

**Other classes of authorized or outstanding equity securities:**

*The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g. preferred shares). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.*

Trading symbol:	
Exact title and class of securities outstanding:	Preferred
CUSIP:	
Par or stated value:	.001
Total shares authorized:	<u>10,000,000</u> as of date: September 30, 2023
Total shares outstanding:	<u>0</u> as of date: <u>September 30, 2023</u>
Total number of shareholders of record:	<u>      </u> as of date: <u>September 30, 2023</u>

Exact title and class of the security:	<u>      </u>
CUSIP (if applicable):	<u>      </u>
Par or stated value:	<u>      </u>
Total shares authorized:	<u>      </u> as of date: <u>      </u>
Total shares outstanding (if applicable):	<u>      </u> as of date: <u>      </u>
Total number of shareholders of record (if applicable):	<u>      </u> as of date: <u>      </u>

**Security Description:**

*The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:*

1. **For common equity, describe any dividend, voting and preemption rights.**

Par value of \$.001 with a 1:1 voting right

2. **For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.**

Full voting rights with common shares holders and converts 1 Preferred Share to 200 Common Shares

3. Describe any other material rights of common or preferred stockholders.

None

4. Describe any material modifications to rights of holders of the company's securities that have occurred over the reporting period covered by this report.

None

### 3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.**

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares, or any other securities or options to acquire such securities, issued for services. Using the tabular format below, please describe these events.

#### A. Changes to the Number of Outstanding Shares

Indicate by check mark whether there were any changes to the number of outstanding shares within the past two completed fiscal years:

No: Yes: ☒ (If yes, you must complete the table below)

Shares Outstanding as of Second Most Recent Fiscal Year End:			*Right-click the rows below and select "Insert" to add rows as needed.						
<u>Opening Balance</u>									
Date <u>12.31.20</u> Common: <u>107,070,281</u> Preferred: <u>10,000,000</u>									
Date of Transaction	Transaction type (e.g., new issuance, cancellation, shares returned to treasury)	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares issued (\$/per share) at Issuance	Were the shares issued at a discount to market price at the time of issuance? (Yes/No)	Individual/ Entity Shares were issued to.  *You must disclose the control person(s) for any entities listed.	Reason for share issuance (e.g. for cash or debt conversion) - OR- Nature of Services Provided	Restricted or Unrestricted as of this filing.	Exemption or Registration Type.
<u>3.13.23</u>	<u>New</u>	430,595,270	<u>Common</u>	<u>.01</u>	<u>No</u>	Hackett, CP As Trustee For Hackett Family Trust	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	319,325,355	<u>Common</u>	<u>.01</u>	<u>No</u>	Todd Leong	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	15,964,205	<u>Common</u>	<u>.01</u>	<u>No</u>	Anne M. Vertovec	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>

<u>3.13.23</u>	<u>New</u>	53,183,615	<u>Common</u>	<u>.01</u>	<u>No</u>	Cynthia R. Klein	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	10,626,585	<u>Common</u>	<u>.01</u>	<u>No</u>	Sharon Anderson Morris	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	26,520,860	<u>Common</u>	<u>.01</u>	<u>No</u>	Robert F. Anderson Revocable Trust	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	53,031,730	<u>Common</u>	<u>.01</u>	<u>No</u>	Albert O. Braun Trust UAD 4/26/2017	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	1,046,915	<u>Common</u>	<u>.01</u>	<u>No</u>	Witold Ostrenko	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	104,664,305	<u>Common</u>	<u>.01</u>	<u>No</u>	Paul Alston	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	52,332,245	<u>Common</u>	<u>.01</u>	<u>No</u>	Henry Morgan Hilliard & Tana Felts Hilliard, JTROS	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	10,436,035	<u>Common</u>	<u>.01</u>	<u>No</u>	Kaulu Holdings, LLC Peter Ciaccia	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	10,409,580	<u>Common</u>	<u>.01</u>	<u>No</u>	Yashna Shetty	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	20,701,685	<u>Common</u>	<u>.01</u>	<u>No</u>	Theresa L. Newsome with Karalyn I. Windebanks and John Kyle Newsome, JTROS	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	17,038,500	<u>Common</u>	<u>.01</u>	<u>No</u>	Ann Vertovec	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	1,020,275	<u>Common</u>	<u>.01</u>	<u>No</u>	Arthur St. C. Wright	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	101,278,620	<u>Common</u>	<u>.01</u>	<u>No</u>	Nicole MacLaren	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	50,517,580	<u>Common</u>	<u>.01</u>	<u>No</u>	Joseph C. Roche and Karen C. Roche, JTROS	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	1,961,000,000	<u>Common</u>	<u>.01</u>	<u>No</u>	Guy M. Zajonc	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	1,147,000,000	<u>Common</u>	<u>.01</u>	<u>No</u>	Michael T. Pfeffer	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	388,500,000	<u>Common</u>	<u>.01</u>	<u>No</u>	Sharon Anderson Morris	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	296,000,000	<u>Common</u>	<u>.01</u>	<u>No</u>	Lisa Bradley	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	150,000,000	<u>Common</u>	<u>.01</u>	<u>No</u>	Felix Inc. <u>Lawrence McGean</u>	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	150,000,000	<u>Common</u>	<u>.01</u>	<u>No</u>	Comfort Inc. <u>Lawrence McGean</u>	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>

<u>3.13.23</u>	<u>New</u>	150,000,000	<u>Common</u>	<u>.01</u>	<u>No</u>	Lago Inc. Colin Thompson	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	129,166,600	<u>Common</u>	<u>.01</u>	<u>No</u>	Ishlex Investment Corp Ltd Gordon Sklenka	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	129,166,600	<u>Common</u>	<u>.01</u>	<u>No</u>	Warmstream Investments Ltd Gary Handley	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	129,166,600	<u>Common</u>	<u>.01</u>	<u>No</u>	Wilura Capital Corp. Charles Ryan	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	150,000,000	<u>Common</u>	<u>.01</u>	<u>No</u>	BT Global Holdings Pty Guy Le Page	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	118,750,000	<u>Common</u>	<u>.01</u>	<u>No</u>	BG Development Fund Pty Ltd Bryce Gould	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	118,750,200	<u>Common</u>	<u>.01</u>	<u>No</u>	Joarch Jagia Investments Pty Ltd Mark Skiffington	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	215,000,000	<u>Common</u>	<u>.01</u>	<u>No</u>	Graycliff Consulting GmbH Susann Prochnow	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	350,000,000	<u>Common</u>	<u>.01</u>	<u>No</u>	Onyx Capital GmbH Torston Prochnow	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	210,000,000	<u>Common</u>	<u>.01</u>	<u>No</u>	Lilly Rose Prochnow	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	66,667	<u>Common</u>	<u>.01</u>	<u>No</u>	Anne M. Vertovec	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	33,333	<u>Common</u>	<u>.01</u>	<u>No</u>	Robert F. Anderson Revocable Trust	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	133,333	<u>Common</u>	<u>.01</u>	<u>No</u>	Albert O. Braun Trust UAD 4/26/2017	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	3,333	<u>Common</u>	<u>.01</u>	<u>No</u>	Arthur St. C. Wright	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	166,667	<u>Common</u>	<u>.01</u>	<u>No</u>	Joseph C. Roche and Karen C. Roche, JTROS	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	33,333	<u>Common</u>	<u>.01</u>	<u>No</u>	Ann M. Vertovec and Betty J. Vertovec, JTROS	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.13.23</u>	<u>New</u>	42,667	<u>Common</u>	<u>.01</u>	<u>No</u>	Brian Hargreaves	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.24.23</u>	<u>New</u>	12,333,395	<u>Common</u>	<u>.01</u>	<u>No</u>	Anne M. Vertovec	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.24.23</u>	<u>New</u>	6,166,605	<u>Common</u>	<u>.01</u>	<u>No</u>	Robert F. Anderson Revocable Trust	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>

<u>3.24.23</u>	<u>New</u>	24,666,605	<u>Common</u>	<u>.01</u>	<u>No</u>	Albert O. Braun Trust UAD 4/26/2017	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.24.23</u>	<u>New</u>	616,605	<u>Common</u>	<u>.01</u>	<u>No</u>	Arthur St. C. Wright	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.24.23</u>	<u>New</u>	30,833,395	<u>Common</u>	<u>.01</u>	<u>No</u>	Joseph C. Roche and Karen C. Roche, JTROS	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.24.23</u>	<u>New</u>	6,166,605	<u>Common</u>	<u>.01</u>	<u>No</u>	Ann M. Vertovec and Betty J. Vertovec, JTROS	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
<u>3.24.23</u>	<u>New</u>	7,893,395	<u>Common</u>	<u>.01</u>	<u>No</u>	Brian Hargreaves	<u>Conversion</u>	<u>Restricted</u>	<u>144</u>
Shares Outstanding on Date of This Report:									
<u>Ending</u> _____ <u>Balance</u>									
<u>Ending Balance:</u>									
Date <u>9.30.2023</u> Common: <u>7,266,940,246</u>									
Preferred: <u>0</u>									

**Example:** A company with a fiscal year end of December 31<sup>st</sup>, in addressing this item for its Annual Report, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2021 through December 31, 2022 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

On March 7, 2023 the total authorized stock was increased to 10,000,000,000 with a par value of \$.001

## B. Promissory and Convertible Notes

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities:

No: ☐ Yes: ☒ (If yes, you must complete the table below)

Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder.  *You must disclose the control person(s) for any entities listed.	Reason for Issuance (e.g. Loan, Services, etc.)
<u>02/23/23</u>	<u>10,361.64</u>	<u>10,000</u>	<u>361.64</u>	<u>02/16/2024</u>	<u>Converts upon a registered financing at the registered price</u>	<u>BT Global Holdings Pty</u> <u>Guy Touzeau Le Page</u>	<u>Loan</u>
<u>02/22/23</u>	<u>10,361.64</u>	<u>10,000</u>	<u>361.64</u>	<u>02/22/24</u>	<u>Converts upon a registered financing at the registered price</u>	<u>Michael Gardner</u>	<u>Loan</u>
<u>02/13/23</u>	<u>10,376.44</u>	<u>10,000</u>	<u>376.44</u>	<u>02/22/24</u>	<u>Converts upon a registered financing at the registered price</u>	<u>Gord Sklenka (Ishlex Investments Corp. Ltd.)</u>	<u>Loan</u>
<u>02/22/23</u>	<u>25,904.11</u>	<u>25,000</u>	<u>904.11</u>	<u>02/22/24</u>	<u>Converts upon a registered</u>	<u>Brenda Chisholm</u>	<u>Loan</u>

					<u>financing at the registered price</u>		
<u>04/20/2023</u>	<u>12,834.93</u>	<u>12,500</u>	<u>334.93</u>	<u>04/20/2024</u>	<u>Converts upon a registered financing at the registered price</u>	<u>BT Global Holdings Pty</u> Guy Touzeau Le Page	<u>Loan</u>
<u>05/03/2023</u>	<u>10,246.58</u>	<u>10,000</u>	<u>246.58</u>	<u>05/03/2024</u>	<u>Converts upon a registered financing at the registered price</u>	Gordon Sklenka (Ishlex Investment Corp Ltd.)	<u>Loan</u>
<u>06/07/23</u>	<u>5,094.52</u>	<u>5,000</u>	<u>94.52</u>	<u>06/07/2024</u>	<u>Converts upon a registered financing at the registered price</u>	Bohdan Leshchushen	<u>Loan</u>
<u>06/14/2023</u>	<u>20,355.07</u>	<u>20,000</u>	<u>355.07</u>	<u>06/20/2024</u>	<u>Converts upon a registered financing at the registered price</u>	<u>BT Global Holdings Pty</u> Guy Touzeau Le Page	<u>Loan</u>
_____	_____	_____	_____	_____	_____	_____	_____

Use the space below to provide any additional details, including footnotes to the table above:

On October 23, 2023, all convertible note stated herein converted to restricted common shares at a conversion price of \$0.01 per common share, this included principal amount and accrued interest up to and including the date of October 23, 2023.

#### 4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations.  
(Please ensure that these descriptions are updated on the Company's Profile on [www.otcmarkets.com](http://www.otcmarkets.com)).

A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

As of March 15, 2023, CNER acquired Thrive Testing and Biosafety Inc., has assumed the business of biodefense with operations in Spokane WA and Hawaii. CNER is no longer a shell company as of March 15, 2023. On October 4, 2023, Thrive changed its name to Thrive Precision Health Inc., and announced it will focus on Precision Diabetes Care through the acquiring and opening of clinics across the USA and Internationally.

B. List any subsidiaries, parent company, or affiliated companies.

Thrive Precision Health Inc. is the parent company (formerly China New Energy Group Company and Thrive Global Biosafety Inc.)

Thrive Testing and Biosafety Inc. is a wholly owned subsidiary of Thrive Precision Health Inc.

Thrive Precision Health Hawaii Inc., was incorporated in the state of Hawaii and is a wholly owned subsidiary of Thrive Precision Health Inc.

Thrive Precision Health USA Inc. was incorporated in the state of Wyoming and is a wholly owned subsidiary of Thrive Precision Health Inc.

C. Describe the issuers' principal products or services.

As of March 15, 2023, CNER acquired Thrive Testing and Biosafety Inc., has assumed the business of biodefense with operations in Spokane WA and Hawaii. CNER is no longer a shell company as of March 15, 2023. On October 4, 2023 the Company shifted it business focus to applying technology to Diabetes Care and renamed the parent company to Thrive Precision Health Inc. Thrive Testing ad Biosafety Inc. will become the core research and development subsidiary focused on adopting and readying technology for adoption among the Diabetes Clinics acquired or started or licensed to external clinics and biosafety companies around the world.



Thrive Precision Health Inc (“TPH”), is focused on the institutionalization of diabetes care through establishing a digital platform that can scale to thousands of clinics across the USA and Internationally. We're acquiring established clinics that already specialize in diabetes care and bringing in three cutting-edge technologies to make them even better. Our goal is to provide top-notch care to patients worldwide, with a seamless digital experience. And we're aiming for a healthy profit margin through technology adoption and digital patient /clinician engagement which means a strong and sustainable business for everyone involved.”

Thrive Testing and Biosafety Inc. (“Thrive”) will be the technology research and development arm, works with leading research and development companies around the world to license enabling technology and adapting it specially to better our clinical and patient operations. Thrive will externally license to other providers especially in the area of of Biosafety. Testing of Bacteria and Viruses on surfaces, in water, in air and in humans in a decentralized basis will speed up detection capabilities with the goal to create a real-time global early warning system and to secure our clinics and patients as well as other clinics. Thrive's goal is to use this system to identify disease breakouts before the next pandemic happens. Thrive 's core strategy is to acquire enabling technology companies and integrate all the technology under one roof, one platform to provide seamless execution on a global scale.

## 5) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties, or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties, or facilities, clearly describe them as above and the terms of their leases.

TPH recently announced the asset purchase of two clinics currently operating in Arizona. These facilities are being leased today, TPH intends to assume these leases upon closure of the asset purchase. Long term leases are being negotiated as of the announcement. In the press release TPH announce the plan to open 30 clinics in Arizona and TPH intends to enter into long term leases for each of these clinics.

## 6) Officers, Directors, and Control Persons

Using the table below, please provide information, as of the period end date of this report, regarding any officers, or directors of the company, individuals or entities controlling more than 5% of any class of the issuers securities, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Names of All Officers, Directors and Control Persons	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Names of control person(s) if a corporate entity

Guy Zajonic	Chairman and CEO	Spokane, WA	1,961,000,000	Common	26.99%	
Michelle Pfiffer	Director and President	Kamuela, HI	1,147,000,000	Common	15.78%	
Hackett, CP	5%+ Shareholder	Australia	430,595,270	Common	5.93%	

## 7) Legal/Disciplinary History

A. Identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

None

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

None

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

None

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None

## 8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

### Securities Counsel (must include Counsel preparing Attorney Letters).

Name: JDT Legal, PLLC Jeff Turner  
Address 1: 897 W. Baxter Dr  
Address 2: South Jordan, UT 84095  
Phone: 801-810-4465  
Email: jeff@jdt-legal.com

### Accountant or Auditor

Name: \_\_\_\_\_  
Firm: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

### Investor Relations

Name: \_\_\_\_\_  
Firm: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_  
Email: \_\_\_\_\_

### *All other means of Investor Communication:*

Twitter: [https://twitter.com/precisiont67828?s=11&t=R3mPh1hAvj9m1R3p\\_\\_8NIA](https://twitter.com/precisiont67828?s=11&t=R3mPh1hAvj9m1R3p__8NIA)  
LinkedIn: <https://www.linkedin.com/company/thrive-precision-health1/>  
Facebook: <https://www.facebook.com/profile.php?id=100092725167875>

### Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: Gary Bartholomew  
Firm: CyberNorth Ventures, Inc  
Nature of Services: Technology Consulting  
Address 1: 2 Campbell Dr, Ste 820  
Address 2: Uxbridge, ON Canada L9P0A3  
Phone: \_\_\_\_\_  
Email: gary@cybernorthventures.com

## 9) Financial Statements

A. The following financial statements were prepared in accordance with:

- ☐ IFRS  
☒ U.S. GAAP

B. The following financial statements were prepared by (name of individual)<sup>2</sup>:

Name: Caren Currier

Title: Consultant

Relationship to Issuer: Consultant

Describe the qualifications of the person or persons who prepared the financial statements: 25 years of experience

Provide the following financial statements for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- a. Audit letter, if audited;
- b. Balance Sheet;
- c. Statement of Income;
- d. Statement of Cash Flows;
- e. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- f. Financial Notes

---

<sup>2</sup> The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

## 10) Issuer Certification

### *Principal Executive Officer:*

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Guy Zajonc certify that:

1. I have reviewed this Disclosure Statement for CHINA NEW ENERGY GROUP COMPANY;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

November 13, 2023 [Date]

/s/Guy Zajonc [CEO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

### *Principal Financial Officer:*

I, Guy Zajonc certify that:

1. I have reviewed this Disclosure Statement for CHINA NEW ENERGY GROUP COMPANY;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

November 14, 2023 [Date]

/s/ Guy Zajonc [CFO's Signature]

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

## NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS

For The Period Ending

June 30, 2023

### NOTE 1: THE COMPANY AND THE SIGNIFICANT ACCOUNTING POLICIES

#### The Company

China New Energy Group Company. (“CNER” or the “Company”) recently renamed, Thrive Global Biosafety Inc, through its wholly owned subsidiary, Thrive Testing and Biosafety Inc. (“Thrive”) works with leading research and development companies around the world to license enabling technology for the delivery of Biosafety as a Service (“BaaS”) to Points of Entry (Airports, Sporting Events, Schools, Business) and to develop a concierge service whereby testing can be ordered and performed on demand at the doorstep of your home or business. Thrive’s purpose is to protect People and Places from pathogens such as bacteria, viruses, fungus, spores, mold and toxins.

#### Basis of presentation

The unaudited consolidated financial statements of the Company have been prepared in accordance with the U.S. Generally Accepted Accounting Principles (“U.S. GAAP”).

### NOTE 2: STOCKHOLDERS EQUITY

As of September 30 2023, and September 30, 2022, the Issuer’s outstanding and authorized common shares and shareholders were approximately as follows:

- (i) September 30, 2023
- (ii) 10,000,000,000 shares of common stock authorized
- (iii) 7,266,940,246 shares of common stock outstanding
- (iv) 535,941,611 common shares are unrestricted:
- (v) 195 shareholders of record
- (i) June 30, 2022
- (ii) 500,000,000 shares of common stock authorized
- (iii) 107,070,281 shares of common stock outstanding
- (iv) 35,941,611 common shares were unrestricted;
- (v) 108 shareholders of record

## **Item 4 Management's Discussion and Analysis or Plan of Operation.**

Management's Discussion and Analysis of Financial Condition and Results of Operations, which we refer to as MD&A, is intended to help the reader understand China New Energy Group Company (named changed to Thrive Precision Health Inc.), our operations and our present business environment. MD&A is provided as a supplement to, and should be read in conjunction with, our financial statements and the accompanying notes for the period ended September 30, 2023.

### **Business Overview**

As of March 15, 2023, CNER acquired Thrive Testing and Biosafety Inc., which has assumed the business of biodefense with operations in Spokane WA and Hawaii. CNER is no longer a shell company as of March 15, 2023.

On April 3, 2023, CNER (China New Energy Group Company) registered a name change in the state of Delaware and CNER is now called Thrive Global Biosafety Inc. Thrive Testing and Biosafety Inc., is a wholly owned subsidiary of Thrive Global Biosafety Inc. Subsequently, Thrive has applied for a name and symbol change with FINRA to reflect the new business of CNER.

On June 28, 2023 Thrive Global Biosafety Inc., incorporated a wholly owned subsidiary in the state of Delaware called Thrive Precision Health Inc.

On October 4, 2023, Thrive Global Biosafety Inc., changed its name to Thrive Precision Health Inc.

On October 7, 2023, Thrive Precision Health Inc., changed its name to Thrive Precision Health Hawaii Inc.

On October 7 2023, Thrive Precision Health Inc. incorporated a wholly owned subsidiary in the state of Wyoming, named Thrive Precision Health USA Inc.

On November 5 2023, Thrive Precision Health Inc. created a not for profit entity called Thrive Precision Health Institute

### **Overview**

Thrive's focus has shifted from purely a biosafety company where it would provide its technology too services companies performing biosafety activities to now applying the breakthrough technology to diabetes care through the acquisition of operating clinics or by startup new clinics in which it will own and operate. Therefore, the parent company renamed itself to Thrive Precision Health Inc. Thrive still maintain the wholly owned subsidiary that have the mandate to commercialize the biosafety technology into Thrive Diabetes Clinics and into other clinics globally.

"We're building a global diabetes care powerhouse. We're acquiring established clinics that already specialize in diabetes care and bringing in three cutting-edge technologies to make them even better. Our goal is to provide top-notch care to patients worldwide, with a seamless digital experience. And we're aiming for a healthy profit margin, which means a strong and sustainable business for everyone involved."

### **How are we doing this?**

"We're taking healthcare to the next level with groundbreaking technology. Imagine if your healthcare was as unique as you are. We're using AI and quantum biosensors to analyze data down to the molecular level, tailoring treatments, and recommendations specifically for you. This means no more one-size-fits-all solutions. Your health decisions will be based on your personal data, ensuring you receive the most effective and personalized care possible."

### **What are we doing?**

**Advanced Technology Adoption:** By incorporating AI and quantum biosensors into our clinics, we are at the forefront of healthcare innovation. This will attract patients looking for cutting-edge solutions, driving adoption.

**Personalized Care:** Our transition from a population health approach to highly individualized precision healthcare means better outcomes and patient satisfaction. Patients are more likely to choose and stick with clinics that offer personalized care.

**Digital Patient Experience:** Today's patients expect a seamless digital experience. Our focus on delivering this enhances patient engagement and loyalty, which in turn drives adoption and repeat business.

**Higher Margins:** Traditional clinics often struggle with inefficiencies and overhead costs. Our tech-driven approach can lead to streamlined operations and reduced costs, ultimately boosting margins.

**Earnings Growth:** With increased adoption, higher margins, and satisfied patients, our clinics are poised for strong earnings growth.

**Valuation:** Investors are increasingly interested in healthcare companies that leverage technology for better patient outcomes and financial returns. Your innovative approach can lead to a higher valuation compared to traditional clinics.

In summary, our strategies not only improve patient care but also make our clinics more efficient and profitable. This combination of technology adoption, personalized care, and a digital patient experience can drive both adoption and valuation well beyond what traditional clinics can achieve in today's competitive healthcare landscape.

### **Technology Strategy:**

Within the operating subsidiary of Thrive Precision Health, called Thrive Testing and Biosafety, technology will be commercialized into diabetes care offered to the patient and protecting the clinic infrastructure from viruses and bacteria (creating a pathogen free safety zone).

## **Technology and Innovation For Clinical Care Delivery:**

### **Overview:**

At our diabetes clinic, we are dedicated to providing comprehensive care to individuals living with diabetes. Our multi-faceted approach encompasses a range of specialized services aimed at enhancing the quality of life for our patients on an individualized basis. Each patient is unique and deserves precision care to optimization their specific needs. Whether you are seeking physiologic insulin resensitization, neuropathy care, wound care, or IV therapies tailored to diabetes health, our clinic is committed to supporting your journey towards improved well-being and better diabetes management.

### **Combined Benefits to Patients:**

1. **Comprehensive Diabetes Management:** Our clinic offers a holistic approach to diabetes care, addressing various aspects of the condition. This comprehensive care model ensures that all aspects of your diabetes management are considered and optimized to use individually.
2. **Improved Quality of Life:** By providing a wide range of services, we aim to enhance the overall quality of life for our patients. Our goal is to minimize the impact of diabetes-related complications and symptoms, allowing you to live a more fulfilling and active life.
3. **Customized Treatment Plans:** Each patient's needs are unique. We develop personalized and precision treatment plans that take into account your specific condition, ensuring that you receive tailored care to achieve the best possible outcomes.
4. **Prevention of Complications:** Our services are designed not only to manage existing diabetes-related issues but also to prevent complications from arising or worsening. Early intervention and proactive care are fundamental to our approach.

### **Specific Treatments for Precision Diabetes Care:**

#### **1. Physiologic Insulin Resensitization:**

Physiologic insulin resensitization is a specialized approach to diabetes management that focuses on restoring the body's sensitivity to insulin through the pulsation of the dose at varying intervals and dosages. This approach treats insulin as a hormone by simulating the pancreatic function versus a full injection of insulin which the body treats as a drug. Re-establishing the pancreatic function has been shown to reverse the effects of Type II diabetes such as wound healing, ischemia, neuropathy and insulin resistance leading to inflammation and weight gain.

#### **2. Neuropathy Care:**

Diabetic neuropathy is a common complication that affects the nerves, leading to symptoms like pain, tingling, and numbness in the extremities. Our clinic provides specialized neuropathy care, including nerve function assessments, pain management strategies, and lifestyle recommendations to alleviate symptoms and prevent further nerve damage. The goal is to improve your comfort and prevent the progression of neuropathy.

#### **3. Wound Care:**

In the world of advanced wound care, where innovation meets compassion, there exists a remarkable treatment option that has been changing the lives of individuals dealing with chronic wounds - amniotic patches. These remarkable medical marvels are derived from the placental tissue of donors and hold within them the potential for accelerated wound healing and tissue regeneration. In our quest to provide the most cutting-edge and effective care to our patients at the diabetes clinic, we have embraced the power of amniotic patches as a vital component of our wound care regimen.



### The Marvel of Amniotic Patches:

Amniotic patches are an extraordinary therapeutic tool that harnesses the regenerative capabilities of placental tissue. They are a rich source of growth factors, cytokines, and extracellular matrix proteins, all of which play crucial roles in tissue repair and regeneration. When applied to chronic or non-healing wounds, these patches create an environment conducive to cellular growth, angiogenesis (the formation of new blood vessels), and tissue remodeling.

### Benefits of Amniotic Patches for Wound Care:

- i. **Enhanced Wound Healing:** Amniotic patches significantly accelerate the healing process of chronic wounds. They stimulate the migration of healthy cells to the wound site, which promotes tissue repair and regeneration.
- ii. **Reduction in Inflammation:** The anti-inflammatory properties of amniotic patches help decrease inflammation at the wound site, reducing pain and discomfort for patients.
- iii. **Minimized Scarring:** By facilitating tissue regeneration, these patches can minimize scarring, leaving patients with a more cosmetically appealing result.
- iv. **Infection Prevention:** The amniotic tissue contains antimicrobial properties that help prevent and combat infections, a common concern in chronic wounds.

### Combining PIR with Amniotic Patches for Better Outcomes:

While amniotic patches offer remarkable benefits in wound care, combining them with our Physiologic Insulin Resensitization (PIR) program can further enhance outcomes for our patients living with diabetes. When PIR is integrated into the patient's treatment plan alongside amniotic patch application, we observe several advantages:

- i. **Improved Blood Flow:** PIR enhances circulation and vascular health, which is crucial for efficient nutrient and oxygen delivery to the wound site, supporting tissue repair facilitated by the amniotic patch.
- ii. **Enhanced Immune Response:** Optimized blood glucose levels through PIR contribute to a stronger immune response, aiding in infection control when using amniotic patches.
- iii. **Reduced Recurrence:** By addressing insulin resistance, PIR helps prevent future wound complications, reducing the likelihood of wound recurrence.

In conclusion, the integration of amniotic patches and PIR in our diabetes clinic represents a holistic approach to wound care that offers our patients the best chance at faster, more complete healing. By combining the regenerative power of amniotic patches with the systemic improvements achieved through PIR, we are dedicated to not only treating wounds but also addressing the underlying factors that contribute to their development in patients with diabetes. It's a testament to our commitment to delivering the most advanced and compassionate care to those we serve.

### 4. IV Therapies for Diabetes Health:

Intravenous (IV) therapies tailored to diabetes health can be beneficial in certain situations, such as severe hyperglycemia or dehydration. Our clinic administers IV therapies to quickly address these issues, helping to stabilize blood sugar levels and restore overall health. These therapies are administered by skilled healthcare professionals with expertise in diabetes care.

In conclusion, our diabetes clinic takes a holistic and patient-centered approach to diabetes management. We offer a range of specialized services that not only address the immediate needs of our patients but also contribute to long-term well-being, emphasizing personalized care and prevention to ensure the best possible outcomes for individuals living with diabetes.

### Clinical Business Model:

Thrive Precision Health business model is to scale a standardized clinical footprint through the USA, starting with 30 clinics in Arizona and expanding rapidly to other high demand states. Each clinic has 20 IV chairs, 5 wound care room and general treatment locations throughout. Our flagship clinic is located in Gilbert, AZ and will represent the standard footprint as we build out.

All services we offer are reimbursed by payers in the USA with the largest being Medicare. As Thrive completes the acquisition of True Health it is our intention to credential with all major payers across the USA.

A small percentage of our business is expected to be cash pay.

## Technology and Innovation for Clinical Biosafety and Global Applications

Thrive's overall strategy is to protect people and places from pathogenic bacteria and viruses with two major focuses on delivering disruptive technology:

1. Through real-time, early detection of Bacteria and Viruses
2. Through innovative treatments for high-risk patient groups such as Diabetics, Elderly that can help the body withstand pathogenic infections.

Thrive Global Biosafety Inc, through its wholly owned subsidiary, Thrive Testing and Biosafety Inc. ("Thrive") work with leading research and development companies around the world to license enabling technology for the delivery of Biosafety as a Service ("BaaS") to its Diabetes Clinics, Points of Entry (Airports, Sporting Events, Schools, Business) and to develop a concierge service whereby testing can be ordered and performed on demand at the doorstep of your home or business. Testing of Bacteria and Viruses on surfaces, in water, in air and in humans and animals on a decentralized basis will speed up detection capabilities with the goal to create a real-time global early warning system. Thrive's goal is to use this system to identify pathogen breakouts before the next pandemic happens. Thrive's core strategy is to acquire enabling technology companies and integrate all the technology under one roof, one platform to provide seamless execution on a global scale.


### Real-Time Detection of Pathogens

**Handheld H2B Model:** Thrive offers two major technologies for real-time microbial detection, Lab on the Go and the H2B handheld highly portable microbial detection technology. Microbials are defined as Bacteria, Fungus, Spores, Mold and certain viruses. The H2B handheld device is a low-cost, but highly sensitive photonics and hyperspectral analysis system that can identify microbial clusters on surfaces. This may be used for pre-sterilization and cleaning assessments, and quality control assessments after the cleaning services have been completed. The unit will be placed near a surface while held in your hand and will scan for microbial colonies. While it can detect a colony, it cannot identify what type of colony is present only the class of microbial (i.e. Bacteria or Fungus). This then requires the Lab on the Go, which is a backpack-style device with an optical cable linked to a handheld sensor.

Lab on the Go – Real Time Lab: is a handheld device with an optical fiber probe aimed to detect Biological and Chemical substances on solid surfaces. It works as a quick screening tool for the status control of surfaces, raw materials, and products in various industries. It is aimed to detect biological and microbial contamination (bacteria, spores, fungi, mold, moss, etc.) in the relevant commercial environment. It is also applicable for the analysis of biophysical characteristics of plant materials, semimanufactures, and ready food products.

The device provides rapid detection directly on-site without sample preparation. The SFS-Probe™ is designed as a compact scanning spectrometer for field operations based on the measurement of the Spectral Fluorescence Signature (SFS) of a controlled object. The SFS represents a "spectral fingerprint" of the sample constituents which are served for their detection and identification. The SFS is measured as an excitation-emission matrix of fluorescence and is visualized as a plot of characteristic-colored spectral patterns (see Figure below). The shape of a spectral pattern is used for substance/object recognition, and the intensity of fluorescence serves as a measure of quantity.





The spectral image is generated in real-time and displayed on a Tablet used by the field technician as they scan suspected surfaces. High bacterial infection areas may be hospital operating rooms, high-traffic areas at airports and train stations, or kitchens in Old Age Care Facilities or Cruise ships. Each bacteria type that has been cataloged produces a unique signature and once scanned the precision GPS location can be communicated to remediation teams. Once the cleaning has been completed, use the Lab on the Go to confirm the cleaning was effective. Resistant bacteria have become a real issue and new cleaning agents and techniques need to be deployed, the Lab on the Go will ensure efficacy. While the H2B Handheld Unit can detect classes of microbials, it can also detect certain viruses such as the Norovirus and the Rotavirus both in a different family of viruses. The Norovirus is highly prevalent worldwide and is a leading cause of gastroenteritis outbreaks, particularly in settings such as:

1. Community settings: Norovirus infections commonly occur in communities, including households, schools, daycare centers, and nursing homes. The virus can spread rapidly in close-contact environments.
2. Cruise ships: Outbreaks of norovirus-associated gastroenteritis on cruise ships have received significant attention due to the confined spaces and close interactions among passengers and crew members.
3. Restaurants and catering establishments: Norovirus can be transmitted through contaminated food and water, leading to outbreaks in restaurants, cafeterias, and other food service settings.
4. Healthcare facilities: Norovirus outbreaks can occur in hospitals, nursing homes, and other healthcare settings. The virus can spread easily among patients, visitors, and healthcare workers.
5. Schools and childcare centers: Norovirus outbreaks are not uncommon in schools and child care facilities, where young children may have limited personal hygiene practices and close interactions.

It's important to note that norovirus can affect anyone regardless of geographical location. However, specific regions may experience higher incidences or outbreaks due to various factors such as population density, sanitation practices, and surveillance systems.

The Rotavirus is prevalent worldwide and is a common cause of severe diarrhea, particularly in young children. The prevalence of rotavirus infections can vary across different regions and is influenced by factors such as sanitation, hygiene practices, access to healthcare, and vaccination coverage. Here are some key points regarding the prevalence of rotavirus:

1. Developing countries: Rotavirus infection is more prevalent in developing countries, particularly in regions with limited access to clean water, sanitation facilities, and healthcare resources. These areas often experience higher rates of severe rotavirus-related diarrhea and associated complications.
2. Sub-Saharan Africa and Asia: Rotavirus-associated diarrhea has been found to be especially common in sub-Saharan Africa and parts of Asia. These regions often have high burdens of rotavirus-related morbidity and mortality.
3. Global impact: Rotavirus infections have a significant global impact, causing millions of cases of severe diarrhea and thousands of deaths each year, predominantly in children under the age of five.
4. Vaccination impact: The introduction of rotavirus vaccines has led to a decline in rotavirus-associated morbidity and mortality in many countries that have implemented routine vaccination programs. However, vaccine coverage varies globally, and the impact of vaccination on rotavirus prevalence can vary across regions.

It's important to note that while rotavirus is more prevalent in certain regions, it can still affect children worldwide. Proper hygiene practices, access to clean water, and the availability of rotavirus vaccines are essential for reducing the burden of rotavirus infections.

## COVID and Influenza Family of Respiratory Viruses Detection

Thrive and its technology partners have adapted the Lab on the Go to read viruses through a patented technology that Thrive has exclusive rights to in Western USA including Hawaii and Alaska. This technology uses a quantum biosensor that reads the presence of the individual virion (virus) in saliva from humans and animals or swabbed off a surface and placed in the liquid quantum biosensor solution. This technology has yet to be commercialized and is in development through a collaboration of scientists and engineers in Canada, the USA, and the EU.

The application for the technology initially will be swabbing surfaces in high-volume locations to detect the virus as it may be present and spreading geographically. This functionality will act as an early warning system for the global spread of the virus. Regulatory approval is not required for the deployment of virus surface detection.

The Lab on the Go has been adapted to read viruses whereby the quantum biosensor is suspended in liquid within a test tube and mixed with the swab sample from a surface collection or saliva sample. The collection and mixing tube is of high quality optical plastic and is placed either in a stationary or handheld reader as shown in the two images below:



*Lab on the Go with Stationary Optical Reader*



*Lab on the Go with Handheld Optical Reader*

It is planned to achieve regulatory approval for testing humans for viruses as part of the early warning pandemic system. The early testing and validation results have been reviewed by the FDA in the USA in August of 2022 and our core technology development partner is developing the full validation report for the FDA to achieve either EUA approval or a full De Novo 510K approval, this has not been determined based on the EUA availability when the validation report is completed.

While regulatory approvals are sought, Thrive will add the technology to its surface detection offering when it becomes available. Currently, the quantum biosensor detects SARS-COVID-2 and its variant with high sensitivity, selectively and specificity enabling detection within 24-48 of contracting the virus. The purpose of early detection is to take precautions if a person is carrying the virus to quarantine themselves to prevent spread.

## Business Model

**Biosafety as a Service Model (BaaS):** The pathogen detection technology will be offered as a service to businesses, the government and the home where a trained biosafety technician will develop a biosafety plan for routine scanning, directing remediation teams and verify the clean-up of the pathogen. Examples could be a cruise ship that is ready for the next departure and wants a scan of the ship as well as the food supply. They may take a small biosafety team with them to scan all food products being loaded on as they stop in each port and scan all new items coming onboard to ensure the safety of their passengers. Continual scans throughout the cruise to ensure proper cleaning and safety. When the quantum biosensor for testing humans is available this can be used to test each passenger before they enter to determine if they are carrying a virus and depending on the virus type quarantine the passenger or deny entry.

The revenue model will vary depending on the size of the biosafety requirements. The H2B Handheld Scanner and the Lab on the Go will be used by Thrive and the pricing will be based on the number of scans required to complete each visit or process. Using the handheld device will be priced into a rapid assessment contract whereas the Lab on the Go will be based on each scan performed as determined in the Biosafety plan for each customer.

For Virus detection, each test will be priced which includes the Biosafety Technician performing the tests throughout the facility.

All data will be uploaded to the cloud-based system and reports and dashboards will be available for the client to review their biosafety status and data.

**Pricing:** Biosafety as a Service will have multiple revenue streams that make up the service offering to any location under contract. Indicative pricing is as follows:

Client Biosafety Plan Development:	\$5,000 to \$50,000 based on the square footage of the facility and safety requirements, including the use of the H2B Scanner to generate the detailed plan.
Bacteria Surface Scan Price:	Volume priced, \$5.00 - \$10.00 per surface scan
Virus Surface Test:	\$25 per surface scan
Detection: Bacteria, Mold and Spores:	Bacteria, Mold and Spores on surfaces. The system can identify the specific signature and be trained to report on specific types in each category.
Detection: Virus on Surfaces:	SARS-CoV-2 direct detection within seconds, and full analysis in 15seconds
	Detects with 99.2% accuracy
	Qualitative Analysis within 15 seconds, Quantitative analysis, 1-2 minutes
	Quantitative Analysis Reports on Viral Load
	Saliva Collection kits, one-step collection and qLMI combined for measurement (requires FDA approval)
	Single-use test kits for Virus Detection (patent pending, requires FDA Approval)
	Uses the Qanik DX qLMI technology for direct detection
Cloud Data:	Different reader for Bacteria, and for Virus (Virus uses the test tube kit)
	A connected system, all data time and location stamped
Custom Dashboards by Use Case:	The cloud system has custom dashboard capability to report critical data
Mobile App:	Dashboards and Location Testing Sites Identified
Other Virus Support	qLMI extensible to other viruses

## Target Biosafety Markets

1. Residential Black Mold: Black mold, also known as *Stachybotrys chartarum*, is just one type of mold among many that can cause health issues and property damage. Mold-related remediation costs can encompass not only the physical removal and treatment of mold but also addressing underlying moisture issues and repairing any structural damage. Mold remediation costs can include expenses related to:

- Professional mold assessment and testing.
- Containment and isolation of the affected area.
- Removal and disposal of mold-infested materials.
- Cleanup and decontamination of surfaces and HVAC systems.
- Restoration or repair of damaged structures.
- Addressing the underlying moisture source to prevent future mold growth.

Exposure to black mold and its spores can have various effects on human health, ranging from mild to severe, depending on individual sensitivity and the extent of exposure. Here are some potential health effects associated with black mold:

- Allergic reactions: Black mold spores can trigger allergic reactions in susceptible individuals. Symptoms may include sneezing, coughing, nasal congestion, itchy or watery eyes, throat irritation, and skin rash.
- Respiratory issues: Prolonged exposure to black mold spores can cause respiratory problems, especially in individuals with pre-existing respiratory conditions such as asthma or allergies. It can lead to increased coughing, wheezing, chest tightness, and difficulty breathing.
- Irritation and inflammation: Contact with black mold or its spores can cause irritation and inflammation of the skin, eyes, nose, throat, and lungs. This can result in redness, itching, sore throat, and coughing.
- Toxic effects: Certain strains of black mold, including *Stachybotrys chartarum*, can produce mycotoxins. Prolonged exposure to high levels of mycotoxins may lead to more severe health effects, such as chronic fatigue, headaches, dizziness, nausea, and in rare cases, severe neurological symptoms.
- Immunocompromised individuals: People with weakened immune systems, such as those undergoing chemotherapy, organ transplant recipients, or individuals with HIV/AIDS, may be more susceptible to fungal infections, including black mold infections.

Mold issues can vary depending on factors such as climate, building conditions, and population density. The following states are often mentioned as having a higher risk or prevalence of mold problems, including black mold:

- Florida: Florida's warm and humid climate can create conditions conducive to mold growth. Hurricanes and heavy rainfall in the state can also lead to water intrusion and increased moisture levels, which contribute to mold issues.
- Texas: Similar to Florida, Texas has a warm and humid climate that can support mold growth. Flooding events, such as those caused by hurricanes or heavy rainstorms, can exacerbate mold problems in the state.
- California: Certain regions of California, particularly coastal areas, can have elevated humidity levels. Moisture intrusion from leaks, as well as water damage resulting from earthquakes or flooding, can contribute to mold growth.
- New York: The presence of older buildings in New York, particularly in densely populated urban areas like New York City, can increase the risk of mold issues. Leaks, inadequate ventilation, and high humidity levels are common factors associated with mold growth.
- Louisiana: Louisiana's warm and humid climate, coupled with frequent heavy rainfall and hurricanes, can create conditions conducive to mold growth. Flooding events, such as those experienced during hurricanes or due to the state's geography, can lead to significant mold problems.

Thrive's service offering is to work with already established Residential Remediation companies that have a local presence across the USA and Globally. The H2B handheld unit can be used in the following ways:

- **Early Detection:** Since mold spores exist naturally in our environment, given the right temperatures and moisture, combined with surfaces the mold spores feed on (drywall, cardboard, wood as an example) catching this growth early and disinfecting the area will save many thousands of dollars of clean-up costs. The H2B handheld biosafety sensor can detect fungus and spores before the black mold occurs in quantity on the surface. Washing the surface or spraying with a disinfectant can prevent further growth. Moisture issues are the main cause, repair within the residence is a must to prevent reoccurrence.
- **Late Detection:** Using the H2B Handheld Biosafety Sensor, the H2B-BM model is used and fitted with a specific optical filter and LED lights to emit within a specific frequency. This is unique to Black mold, versus Fungus and Spores which used the standard unit. Black may be visible to the human eye (in this case its very advanced) however detection areas that are not visible will be critical to the remediation to ensure complete clean up. Advanced level Black Mold may require walls, and interiors of a building to be removed costing \$10's or \$100's of thousands of dollars.

2. **Food Security:** Several bacteria pose significant threats to food security around the World. The following are some notable bacteria associated with foodborne illnesses and their potential impact on food safety:

- **Salmonella:** Salmonella is one of the most common bacterial pathogens associated with foodborne illnesses in the U.S. It can contaminate various food products, including poultry, eggs, dairy products, fruits, and vegetables.
- **Escherichia coli (E. coli):** Certain strains of E. coli, such as Shiga toxin-producing E. coli (STEC), can cause severe foodborne illnesses. Contaminated ground beef, raw produce, unpasteurized milk, and contaminated water are common sources of E. coli infections.
- **Campylobacter:** Campylobacter is a leading cause of bacterial gastroenteritis in the United States. It is commonly associated with undercooked poultry, unpasteurized milk, and contaminated water.
- **Listeria monocytogenes:** Listeria monocytogenes is a particularly concerning bacterium as it can cause severe illnesses, especially in vulnerable populations such as pregnant women, older adults, and individuals with weakened immune systems. It can contaminate various foods, including deli meats, soft cheeses, and ready-to-eat foods.
- **Clostridium perfringens:** Clostridium perfringens is often associated with foodborne outbreaks, particularly in large-scale food service settings. It is commonly found in improperly handled or stored cooked meats, gravies, and stews.
- **Vibrio species:** Vibrio species, particularly Vibrio vulnificus and Vibrio parahaemolyticus, can cause infections related to the consumption of raw or undercooked seafood, especially oysters and shellfish.

These are just a few examples, and there are other bacteria, viruses, and parasites that can also pose food safety risks. It's important to note that food safety practices, including proper food handling, storage, cooking, and sanitation, play a crucial role in reducing the risk of foodborne illnesses. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the U.S. Department of Agriculture (USDA), work to establish and enforce standards and guidelines to ensure food safety throughout the food production and distribution chain.

In the United States, the most prevalent category of food associated with foodborne illnesses can vary depending on several factors, including the year, region, and specific outbreaks. However, certain food categories have been consistently linked to a significant number of foodborne illness cases. These include:

- **Poultry:** Chicken and turkey have been frequently associated with foodborne illnesses, particularly those caused by Salmonella and Campylobacter. Improper handling, undercooking, and cross-contamination during poultry processing and preparation can contribute to the risk.
- **Produce:** Fresh fruits and vegetables have been implicated in several outbreaks due to contamination with pathogens like Salmonella, E. coli, and Listeria. Contamination can occur through contact with contaminated water, soil, or improper handling during harvesting, processing, or preparation.
- **Dairy Products:** Raw or unpasteurized milk, as well as cheeses made from raw milk, have been linked to outbreaks of foodborne illnesses caused by pathogens like Salmonella, E. coli, and Listeria. Pasteurization is a crucial step in reducing the risk of bacterial contamination in dairy products.
- **Ground Meat:** Ground beef and other ground meats, when improperly handled or undercooked, can harbor harmful bacteria like E. coli and Salmonella. Contamination can occur during slaughter, processing, or due to cross-contamination during storage and cooking.




- **Seafood:** Raw or undercooked seafood, especially oysters and shellfish, have been associated with foodborne illnesses caused by *Vibrio* species, including *Vibrio vulnificus* and *Vibrio parahaemolyticus*. Seafood can become contaminated due to exposure to contaminated waters or improper handling during processing and preparation.

It's important to note that while these food categories have been frequently linked to foodborne illnesses, it does not mean that all products within these categories are unsafe. Following proper food safety practices, such as thorough cooking, good hygiene, proper storage, and purchasing from reputable sources, can help minimize the risk of foodborne illnesses.

Thrive has two technology offerings to enhance food security which can occur at the importation process (the Food Terminal) or daily within grocery stores, restaurants, or the home. For rapid assessment, using the H2B handheld biosafety sensor bacteria and certain viral clusters can be detected which then require further investigation. The H2B can indicate the presence of Bacteria, Mold, Spores, Fungus and certain Viruses. If there is an indication and further investigation is required, Lab on the Go can be used to identify the specific type of pathogen further allowing the purchaser or seller to decide if remediation is possible or complete destruction of the food.

Applications for this technology as it related to Food Security are the Cruise Industry, inspecting food before it comes onboard at each location they stop to restock. Food terminals where mass distribution to retail and restaurants occurs as well as growers/producers to verify soil and irrigation systems, meat processing facilities, etc. The diagram below shows the spectral signature for various microbial contamination using the Lab on the Go:



Each microbe emits a unique spectral signature that's stored in a global database for the Lab on the Go to access in order to identify the specific microbe. This database of signatures is growing as biosafety teams continually find unique and new microbes. If a new signature is found and does not exist in the global signature database, then the sample will be taken to a traditions lab and RNA/DNA analysis will be performed to identify the microbe. This data is then entered into the global database. As microbes continue to mutate and evolve this will be an ongoing process globally to build a every growing signature database.

3. **Other Market Verticals for Biosafety Services:** While the original focus for Biosafety will be on microbial contamination with Residential//Commercial Black Mold and Food Security, there are many other sectors Thrive is exploring as follows:
  - Hospitals, Clinics and Healthcare, due to hospital born infections due to poor sterilization procedures.
  - Assisted Living Homes, many seniors are susceptible to bacterial and viral infections.
  - Travel Security, airports, train stations, bus stations, and high-volume areas that promote the spread of viruses and bacteria.
  - Office Building and Factories, virus and bacterial spread through the workplace and manufacturing facilities
  - BioDefense, military applications for early detection of man-made pathogens like anthrax, engineered bacteria and viruses. Real time detection on the front lines is currently in use with the EU military.



- Schools, Universities to keep our children and teachers safe.
- At Home, a mobile Uber style biosafety business to order in testing of surfaces, water, air or humans and animals (some of which required FDA approvals)

#### Item 5 Legal Proceedings.

None

#### Item 6 Defaults on Senior Securities.

None.

#### Item 7 Other Information.

Subsequent Material Events:

Aug 18, 2023, Thrive Precision Health Inc. provided a financial guarantee for \$98,132.00 to be settled in the common restricted shares of Thrive Precision Health Inc. at a price of \$0.01 share. Proceeds of the loan was to fund clinical operations of True Diabetes Neuropathy and Wounds Solutions LLC in Arizona.

Aug 22, 2023, Thrive Precision Health inc., entered into a \$20,000.00 Promissory Note with Elysian Essential Oils LLC, an entity owned by David Anderson a shareholder of Thrive Precision Health, accruing interest at 6% annually with a 120-day term. Two repayments have been made: On Oct. 4, 2023, \$5,000 was repaid and on October 28, 2023, \$7,500 was repaid. Therefore, \$7,500 plus accrued interest remains a loan and interest liability of Thrive.

Sept 1, 2023, Thrive Precision Health Inc., signed an agreement to purchase 100% of the assets of True Diabetes Neuropathy and Wounds Solutions LLC which includes Gilbert and Slow Low locations in Arizona.

Oct 23, 2023, Thrive Precision Health Inc, closed a private placement financing and issued 75,592,246 restricted common shares. This issued consisted of capital invested of \$650,000.00 and the conversion of all convertible promissory notes principle and accrued interest outstanding as of October 23, 2023. The following table details the conversion amounts and share issuance totaling 10,592,246 restricted common shares with a conversion price of \$0.01:

Shareholder name	Date Funds received	Principle Invested	Interest Rate	Day for Accrual	Dollar Amount Accrued	Total Settled at 1 cent	Total Restricted Shares Issued
Prom Note - BT Global Holdings Pty Ltd.	22-Feb-23	\$10,000.00	6%	243	\$399.45	\$10,399.45	1,039,945
Prom Note - Venex Inc. (Register as Ishlex Investment Corp Ltd)	13-Feb-23	\$10,000.00	6%	252	\$414.25	\$10,414.25	1,041,425
Prom Note - Brenda Chisolm	22-Feb-23	\$25,000.00	6%	243	\$998.63	\$25,998.63	2,599,863
Prom Note - Michael Gardner	22-Feb-23	\$10,000.00	6%	243	\$399.45	\$10,399.45	1,039,945
Prom Note - BT Global Holdings Pty Ltd.	20-Apr-23	\$12,500.00	6%	186	\$382.19	\$12,882.19	1,288,219
Prom Note Gord Sklenka (register as Ishlex Investment Corp Ltd)	03-May-23	\$10,000.00	6%	173	\$284.38	\$10,284.38	1,028,438
Prom Note - BT Global Holdings Pty Ltd.	14-Jun-23	\$20,000.00	6%	131	\$430.68	\$20,430.68	2,043,068
Prom Note - Bohdan Leshchushen	07-Jun-23	\$5,000.00	6%	138	\$113.42	\$5,113.42	511,342
		<b>\$102,500.00</b>				<b>\$105,922.47</b>	<b>10,592,247</b>

**CNER**  
**Balance Sheet Prev Year Comparison**  
**As of September 30, 2023**

	Sep 30, 23	Sep 30, 22
<b>ASSETS</b>		
Current Assets		
Checking/Savings	17,566.54	0.00
Total Current Assets	17,566.54	0.00
Other Assets	420,500.00	0.00
<b>TOTAL ASSETS</b>	<b>438,066.54</b>	<b>0.00</b>
<b>LIABILITIES &amp; EQUITY</b>		
Liabilities		
Current Liabilities		
Accounts Payable	5,344.87	0.00
Other Current Liabilities		
Accruals and other payables	3,060.40	2,701.55
Due to Guy Zajonc	4,020.00	0.00
Due to Related Party	24,398.06	24,378.06
Kaleu Holdings, LLC	25,000.00	0.00
Loan - Bohdan Leshchusen	5,018.90	0.00
Loan - Brenda Chisholm	25,530.14	0.00
Loan - BT Global	42,902.75	0.00
Loan - Gord Sklenka	10,212.02	0.00
Loan - Michael Gardner	10,212.02	0.00
Loan - Venex	10,212.02	0.00
Loans from Shareholders	992,600.00	0.00
Note Payable - Elysian Essentia	20,000.00	0.00
Synergy Wounds Solutions	50,000.00	0.00
Total Other Current Liabilities	1,223,166.31	27,079.61
Total Current Liabilities	1,228,511.18	27,079.61
Total Liabilities	1,228,511.18	27,079.61
Equity		
Additonal Paid In Capital	-20,984,614.00	-14,827,344.00
All Stock		
Common Stock	7,266,940.00	107,070.00
Series A - Preferred Stock	0.00	10,000.00
Total All Stock	7,266,940.00	117,070.00
Accumulated Deficit	12,927,229.36	14,683,194.39
Total Equity	-790,444.64	-27,079.61
<b>TOTAL LIABILITIES &amp; EQUITY</b>	<b>438,066.54</b>	<b>0.00</b>

**CNER**  
**Statement of Cash Flows**  
 July through September 2023

---

	<u>Jul - Sep 23</u>
<b>OPERATING ACTIVITIES</b>	
Net Income	-1,065,047.19
Adjustments to reconcile Net Income to net cash provided by operations:	
*Accounts Payable	4,810.00
Accounts Payable	-7,224.16
Due to Related Party	20.00
Kaleu Holdings, LLC	25,000.00
Loans from Shareholders	992,600.00
Note Payable - Elysian Essentia	20,000.00
Synergy Wounds Solutions	50,000.00
Net cash provided by Operating Activities	20,158.65
<b>INVESTING ACTIVITIES</b>	
Long Term Investments	-3,500.00
Net cash provided by Investing Activities	-3,500.00
Net cash increase for period	16,658.65
Cash at beginning of period	907.89
Cash at end of period	<u><u>17,566.54</u></u>

2:31 PM

11/13/23

Accrual Basis

**CNER**  
**Profit & Loss Prev Year Comparison**  
**July through September 2023**

---

	Jul - Sep 23	Jul - Sep 22
Ordinary Income/Expense		
Expense		
Dues and Subscriptions	96.00	0.00
Office Supplies	140.35	0.00
Professional Fees		
Legal Fees	3,650.00	0.00
Professional Fees - Other	0.00	500.00
Total Professional Fees	3,650.00	500.00
Transfer Agenet Fees	4,810.00	701.55
Total Expense	8,696.35	1,201.55
Net Ordinary Income	-8,696.35	-1,201.55
Other Income/Expense		
Other Expense	1,056,350.84	0.00
Net Other Income	-1,056,350.84	0.00
Net Income	<b>-1,065,047.19</b>	<b>-1,201.55</b>

China New Energy  
Shareholders' Equity (Deficiency)  
(Unaudited)

	Common Stock		Preferred Stock - Class A		Preferred Stock - Class B		Preferred Stock - Class C		Add'l Paid	Accumulated	Total Stockholders'
	Shares	Amount	Shares	Amount	Shares	Amount	Shares	Amount	in Capital	Deficit/Profit	Equity/(Deficit)
Balance March 31, 2022	107,070,281	107,070	10,000,000	10,000	-	-	-	-	(14,831,884)	14,699,866	(14,878)
Shares Issued											-
Net Gain/(loss) for period ended June 30, 2022									4,500	(4,500)	-
Balance June 30, 2022	107,070,281	107,070	10,000,000	10,000	-	-	-	-	(14,827,384)	14,695,366	(14,878)
Shares Issued											-
Net Gain/(loss) for period ended September 30, 2022									-	(1,202)	(1,202)
Balance September 30, 2022	107,070,281	107,070	10,000,000	10,000	-	-	-	-	(14,827,384)	14,694,164	(16,080)
Shares Issued											-
Net Gain/(loss) for period ended December 31, 2022									-	(359)	(359)
Balance December 31, 2022	107,070,281	107,070	10,000,000	10,000	-	-	-	-	(14,827,384)	14,693,875	(16,439)
Thrive Gain/Loss										(513,832)	(513,832)
Net Gain/(loss) for period ended March 31, 2023	7,159,869,965	7,159,870	(10,000,000)	(10,000)					(6,157,230)	(111,071)	881,569
Balance March 31, 2023	7,266,940,246	7,266,940	-	-	-	-	-	-	(20,984,614)	14,068,972	351,298
Thrive Gain/Loss											-
Net Gain/(loss) for period ended June 30, 2023										(76,696)	(76,696)
Balance June 30, 2023	7,266,940,246	7,266,940	-	-	-	-	-	-	(20,984,614)	13,992,276	274,602
Thrive Gain/Loss											-
Net Gain/(loss) for period ended September 30, 2023										(1,065,047)	(1,065,047)
Balance September 30, 2023	7,266,940,246	7,266,940	-	-	-	-	-	-	(20,984,614)	12,927,229	(790,445)